University of Windsor

Scholarship at UWindsor
Electronic Theses and Dissertations

Theses, Dissertations, and Major Papers

10-30-2020

Mechanism Determination of the Effects of Pancratistatin on
Model Mitochondrial Membranes
Brett William Rickeard
University of Windsor

Follow this and additional works at: https://scholar.uwindsor.ca/etd

Recommended Citation
Rickeard, Brett William, "Mechanism Determination of the Effects of Pancratistatin on Model
Mitochondrial Membranes" (2020). Electronic Theses and Dissertations. 8475.
https://scholar.uwindsor.ca/etd/8475

This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor
students from 1954 forward. These documents are made available for personal study and research purposes only,
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution,
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or
thesis from this database. For additional inquiries, please contact the repository administrator via email
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208.

Mechanism Determination of the
Effects of Pancratistatin on Model
Mitochondrial Membranes

By

Brett W. Rickeard

A Thesis
Submitted to the Faculty of Graduate Studies
through the Department of Chemistry and Biochemistry
in Partial Fulfillment of the Requirements for
the Degree of Masters of Science
at the University of Windsor

Windsor, Ontario, Canada
2020

c 2020 Brett W. Rickeard

Mechanism Determination of the Effects of Pancratistatin on
Model Mitochondrial Membranes
by
Brett W. Rickeard

APPROVED BY:

J. Dason
Department of Biomedical Sciences

S. Pandey
Department of Chemistry & Biochemistry

D. Marquardt, Advisor
Department of Chemistry & Biochemistry

August 25, 2020

Declaration of Originality
I hereby certify that I am the sole author of this thesis and that no part of this thesis has
been published or submitted for publication.
I certify that, to the best of my knowledge, my thesis does not infringe upon anyone’s
copyright nor violate any proprietary rights and that any ideas, techniques, quotations,
or any other material from the work of other people included in my thesis, published or
otherwise, are fully acknowledged in accordance with the standard referencing practices.
Furthermore, to the extent that I have included copyrighted material that surpasses the
bounds of fair dealing within the meaning of the Canada Copyright Act, I certify that I
have obtained a written permission from the copyright owner(s) to include such material(s)
in my thesis and have included copies of such copyright clearances to my appendix.
I declare that this is a true copy of my thesis, including any final revisions, as approved
by my thesis committee and the Graduate Studies office, and that this thesis has not been
submitted for a higher degree to any other University or Institution.

iii

Abstract
Apoptosis is programmed cell death that is essential for physiological development
and tissue homeostasis. From a biochemical standpoint, this process can be exploited to
target and eliminate specific cell types, such as cancer cells. Pancratistatin (PST) is an
antiviral alkaloid metabolite that has demonstrated directed apoptotic action on various
human cancer cell lines while having minimal/no toxic effect on normal cells. However,
PST’s mechanism of action remains uncertain. To better understand how PST induces its
anti-cancer action various biophysical techniques were employed. Neutron spin-echo (NSE)
spectroscopy was used to examine how PST impacted the bending fluctuations of large unilamellar vesicles (LUVs) bearing a lipid composition meant to mimic the inner mitochondrial
membranes (IMM). The IMM mimic was composed of three lipids: 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine
(POPE), and tetraoleoyl cardiolipin (TOCL). Small-angle neutron and X-ray scattering
(SANS and SAXS) were utilized to determine how PST influences membranes structure.
Molecular dynamics (MD) simulations were used to compliment the data gathered from
the scattering experiments, while also examining lipid chain order, PST localization and
the PST-lipid relationships. The results show that PST has a condensing effect the IMM
mimic. This thesis elaborates on the possible implications of this finding with regard to
the nature of PST’s interaction with the IMM mimic and proposes a hypothesis for the
anti-cancer mechanism of PST.
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Chapter 1

Introduction
1.1
1.1.1

Model Membranes
Purpose, Utility and Limitations
Biological membranes are extremely complex components of cells. They are composed

of two lipid leaflets that house a variety of a macromolecules, where the composition of the
membrane and its associated macromolecules is based on cell type. The main function of
a biomembrane is to provide a selectively permeable barrier, defining cells or organelles
within cells. Many biochemical processes depend on the structural diversity and physical
properties of biomembranes, such as: cell volume maintenance [1, 2], cellular signalling
[3–5], energy production [6–8], toxin defence [9], macromolecule transportation [10, 11], pH
regulation [12] and protein function [13–16].
The relevance of biomembranes has motivated the development of simpler model systems that are tailored to represent the size, shape and composition of the desired biological
membrane. Model membranes enable experimenters to pinpoint the role of certain macromolecules in membrane associated interactions by isolating different aspects of membrane
functionality, providing an insight into the bigger picture. Extracting similar information
from a biomembrane would be problematic due to their crowded nature. Model membranes
have been used to study the structural properties of lipids [17–19], membrane heterogeneity
[20–23] and interactions between lipids and drugs or other molecules [24–28].
1
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Model membranes have proven utility, but it is important to acknowledge their limitations. They lack the overall intricacy of a biomembrane, as they are typically composed of
only 1-3 lipids and another biological or synthetic molecule [29]. Consequently, the reduced
structure of model membrane can be seen as restriction regarding its biological mimicry
[30].

1.1.2

Classification and Nomenclature
Model membranes can be constructed in using a variety of methods, however for

the purposes of this thesis free-floating phospholipid vesicles will be the focus. Free floating
vesicles are hollow spheres composed of a lipid bilayer or multiple bilayers in aqueous solution
with a buffer filled lumen. Vesicles with a single bilayer are referred to as unilamellar vesicles,
while vesicles with multiple bilayers is a multilamellar vesicles (MLV)s, as shown in Figure
1.1.

Figure 1.1: The morphological difference between MLVs (A) and unilamellar vesicles (B).

In terms of size, vesicles are classified based on their diameter in nanometers. MLVs
tend to be quite large due to their multiple layers, this results in a diameter of 500 nm or
greater [31]. Unilamellar vesicles can fall within three main size groups: small unilamellar
vesicles (SUVs), large unilamellar vesicles (LUVs) and giant unilamellar vesicles (GUVs).
The difference between these vesicle size classes can be seen in Table 1.1 [32].
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Vesicle Type

Diameter Range (nm)

SUV

20 - 50

LUV

50 - 500

GUV

≥ 500

Table 1.1: Table outlining the diameters of SUVs, LUVs and GUVs.

Based on size alone GUVs are the most accurate resemblance of eukaryotic cells,
which have a diameters of 10,000-30,000 nm [33]. However, GUVs are more susceptible to
shrinking or even bursting when interacting with an external molecule [34]. LUVs are small
relative to biological cells, but they are quite stable and lack the influence of membrane
curvature seen in SUVs [18]. Hence, LUVs deliver a size frame that is a stable and suitable
model membrane.

1.2

Mitochondria
The mitochondria is an organelle found in most eukaryotic organisms and is respon-

sible for energy generation and metabolism regulation. They are semi autonomous and
have a unique double membrane bound structure. For the purpose of this thesis the inner
mitochondrial membrane (IMM) will be the focus considering the drug of interest targets
the IMM [35–37].

1.2.1

The Inner Mitochondrial Membrane
The IMM also creates a boundary, isolating the more viscous mitochondrial matrix

from the more cytosolic intermembrane space. The IMM also houses the electron transport
chain (ETC) which produces the majority of the cell’s chemical energy, adenosine triphostphate (ATP). The IMM has a extensive network of folds known as cristae. The cristae
greatly increase the surface area of the IMM such that more working space is available
for ATP production [38]. A wide variety of lipids form the IMM in eukaryotes, with phosphatidylcholine (PC) being the most abundant, followed by phosphatidylethanolamine (PE)
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and cardiolipin [39–42]. Cardiolipin’s distinctive features and functions will be discussed
further in section 1.2.2.
Reactive oxygen species (ROS) are produced by the ETC of the IMM. Electron leakage in the ETC induces the partial reduction of oxygen species to form ROS like superoxide
and hydrogen peroxide [43, 44]. ROS are important signalling molecules involved in the
regulation of inflammation during stress [45]. Conversely, high levels of ROS can be harmful to the cell as they can cause damage to genetic material [46] and trigger apoptosis and
autophagy pathways [45].
Permeability is a key feature of the IMM. Water, carbon dioxide and oxygen can
easily cross the IMM, while small ions like protons require specialized ion transporters or
channels to cross the barrier [47, 48]. This selective permeability leads to a difference in
membrane potential, an essential driving force for ATP synthesis. However, if the IMM
potential is disrupted it can lead to a decrease in mitochondria performance, or even cell
death via the triggering of apoptotic proteins by cytochrome c release from the IMM [49–52].

1.2.2

Cardiolipin
Cardiolipin (CL) is a class of phospholipids found almost exclusively in the IMM

of eukaryotes [53]. Many pathological issues can arise from CL shortage or degradation,
including Barth syndrome, neurodegenerative diseases, heart failure and Tangier disease
[54–56]. CL is a structurally irregular lipid (see Figure 1.2 in that is has two linked phosphate
headgroups, both of which are connected to two hydrocarbon chains via a glycerol backbone
[57].

Figure 1.2: A cartoon representation of the basic structure of CL.
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Although the behaviour of CL has been understudied, some deductions have been
made. CL has the capability to carry two negative charges on its phosphate moieties
depending on local pH [58]. These negative charges can bind to cationic species on proteins
or other molecules. Recent literature has shown that CL’s negative charges play a key role in
the stabilization of key lysine residues on ATP synthase, permitting consistent functionality
[7]. Similarily, CL has been shown to influence the active site of complex I, making it more
accessible to the substrate [16]. CL also aids the complexes of the ETC in an indirect
manner. The negative charges permit CL to act as a proton reservoir around the ETC
complexes, ensuring that minimal pH charge occurs during proton pump operation [59].
Furthermore, CL is involved in apoptosis, as CL anchors cytochrome c to the IMM and
upon disruption of this electrostatic interaction cytochrome c can be released, bringing
about an apoptotic cascade [60, 61].
From a biophysical standpoint, CL has a compact headgroup that limits the movement of its phosphate groups while having a large hydrophobic character due to its four
hydrocarbon tails. The stark contrast between the small polar headgroup and hydrophobic hydrocarbons gives CL a high degree of negative curvature. As a result CL tends to
form inverted non-lamellar lipid phases [62] and can be found in areas with high membrane
curvature, such as the cristae [63]. CL’s localization at areas of high curvature have lead
to finding regarding CL platforms or rafts [64, 65]. These CL rich regions are associated
with improving protein functionality by providing a practical platform [3, 20, 63]. CL has
a low propensity for hydrogen bonding, as only the hydroxyl group of the glycerol in the
headgroup is capable of hydrogen bonding. In combination with the limited mobility of
the headgroup, the limited hydrogen bonding ability of CL leads to very little intermolecular hydrogen bonding between CL headgroups [66]. This lack of internal interaction is
dissimilar to that most lipids. Thus CL has a lack a self induced shielding, making its negative phosphate groups more accessible to water, ions, drugs and membrane bound proteins
[66, 67].

1.2.3

Cancer and the Mitochondria
In healthy people cells grow and divide at a normal rate to satisfy the requirements

of the body. Cells will be replaced as they grow old or suffer an injury, resulting in impaired
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functionality. When cancer develops the process stated above changes in a negative manner.
Cancer is caused by multiple changes in gene expression, leading to the dysregulation of
standard cell programming for cell proliferation and differentiation [68]. This causes abnormal cell growth that can invade surrounding tissue and spread to other regions of the
body. These elements of cancer impede tissue and organ functionality, leading to death
if left untreated. Cancer development is attributed to numerous factors including genetic
susceptibility, lifestyle choices and interactions with carcinogenic substances [69].
Cancer is one of the most common and deadly diseases in the world today, despite the
meticulous efforts towards cancer research. The World Health Organization reports that
cancer is responsible for roughly 1 in 6 deaths and is the second leading cause of mortality
globally [70]. In Canada cancer is a leading cause of death, in 2016 it was responsible for
30% of all Canadian deaths [71]. Certain types of cancers are more prevalent than others,
as the Canadian Cancer Society states that lung, breast, colorectal and prostate cancer
account for 50% of newly diagnosed cancer cases [71].
Several differences exist between cancer mitochondria and healthy mitochondria.
Firstly, transformed cells have a higher rate a proliferation and more metabolic demands
as a consequence. This stress causes irregular lipid remodelling in the mitochondrial membranes, leading to complications with mitochondrial fusion and fission, as well as impairing
the ETC [72]. Secondly, cancer cells rely heavily on glycolysis in the presence of oxygen,
accordingly termed aerobic glycolysis, for the generation of ATP [73, 74]. The shift to
aerobic glycolysis favours cancer cells in that proliferation and energy generation can occur
under varying oxygen conditions [75]. The dependence on glycolysis yields a more acidic
cytosol due to large amounts of pyruvate and lactate, promoting membrane hyper polarization while simultaneously disrupting the ETC and increasing ROS abundance [76, 77]. In
contrast, many studies have shown that the mitochondria remain functional in numerous
cancers [78–86]. Cancer cells may indeed depend on both oxidative phosphorylation and
aerobic respiration to cater to the demanding energetic needs of cancer cells [87–89]. Some
cancer cell lean laboriously on oxidative phosphorylation to produce ATP due to preference or metabolic necessity [90–92]. Moreover, cancer cells exhibit higher concentrations
of Bcl-2 proteins. These proteins help protect cancer mitochondria by making them less
vulnerable to mitochondria membrane permeabilization [93]. These unique features of can-

Chapter 1. Introduction

7

cer cell mitochondria have presented attributes that can be exploited for the purpose of
selectively targeting cancer cells. Compounds that seek to target cancer mitochondria are
termed mitocans and they aim to disrupt the ETC, inhibit Bcl-2 proteins, increase mitochondrial membrane permeability, increase ROS concentration and target the compromised
mitochondrial assembly [94, 95].

1.3

Pancratistatin
Plants of the Amaryllidaceae family have been used to treat numerous diseases

throughout history [96]. The Hymenocallis littoralis, better known as the spider lily, is
a member the Amaryllidaceae plant family. Fueled by possible health implications, the
biochemical compounds found in Hymenocallis littoralis were extracted, leading to the discovery of pancratistatin (PST) by Pettit et al. in 1984 [97, 98]. The chemical structure of
PST can be seen in 1.3.

Figure 1.3: The chemical structure of PST.

1.3.1

Anti-Cancer Activity
Current cancer research has strived to find compounds, such as mitocans, that can

upset biochemical processes in cancer cells while having little to no toxic impact on adjacent
healthy cells. PST is a mitocan that has demonstrates this attractive ability, as previous
studies have shown its selectivity between cancerous and healthy cells [35–37, 99–102].
PST’s anti-cancer capabilities are evident in a number of human cancer types including
leukemia [101], colorectal cancer [102], prostate cancer [37], breast cancer [36], human neu-
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roblastoma [35], lymphoma [99] and melanoma [100]. Cancer mitochondria are the target
of PST; it causes an early increase ROS concentration, loss of mitochondrial membrane
potential, decrease in ATP output, and initiation of apoptotic agents [35–37, 99–102]. Although PST has proven ability as a mitocan, the mechanism at which this ability stems
from remains elusive [99].

1.4

Objectives
The present study looks to advance and expand on the previous research of PST

and its operational mechanism with respect to the IMM. Little to no investigation into the
impact of PST on membrane biophysics has been undertaken. The objectives of this thesis
include:
1. Study the influence of PST on model IMM dynamics.
2. Examine how PST changes structural parameters of the model IMM.
3. Deduce if a relationship exists between the different lipid species in the model IMM and
PST and the possible implications of this connection.

Chapter 2

Experimental Techniques
2.1

Small-Angle Scattering
Small-angle scattering (SAS) is a scattering technique used to extract structural

properties of a sample based on how it deflects incoming radiation. The wavelength of the
incident radiation (typically 1-12 Å depending on radiation type) is much smaller than the
sample itself (>50 nm for most lipid vesicles), resulting in a small deflection angle and giving
the technique its name [103]. SAS is an elastic scattering technique, meaning their is no
energy transfer during interactions between the sample and the radiation. Thus, information
regarding the structure, size, shape, and orientation of bilayers and lipids within bilayers
can be extracted at a high resolution without the influence of energy fluctuations [103–
106]. SAS provides some distinct advantages with regards to analyzing biological samples.
It provides structural information about fractionally or completely disordered systems, it
can study supramolecular structures in physiologically relevant environments and it is nondestructive [103]. Other techniques typically require probes to exact similar information,
perturbing the membrane in the process [107].
SAS techniques operate by shining monochromatic radiation onto a sample, which
consequently scatters at an angle onto a two-dimensional detector. The one-dimensional
radial average of the scattered radiation is then taken, which determines the amount of
particles present at at given distance away from a reference particle. The radial average can

9
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be manipulated to generate a form factor; a numerical representation of the size, shape and
arrangement of the particles in a sample. A visual representation of how the radial average
translates to the form factor can be seen in Figure 2.1 by way of the colour gradient shown
on the detector and the corresponding form factor.

Figure 2.1: Schematic of how SAS works, highlighting how the radial average translates
to a form factor.

The scattering vector, q, can be used to interpret the form factor. The q values are
determined by scattering angle (2θ) as shown by the following equation:

q=

4πsinθ
λ

(2.1.1)

In equation 2.1.1, 2θ represents the angle between the incident radiation and the scattered
radiation, while λ represents the wavelength of the radiation. The scattering vector is
the resolution or yardstick by which the sample is being viewed [103]. Therefore, as the
magnitude of q changes, different sized structural features can be analyzed. The value of q
is inversely related to size in real space. In vesicles, low q is used to interpret interactions
between vesicles or vesicles and a foreign substance, intermediate q looks at membrane
features such as bilayer thickness and high q examines lipid properties and interactions like
area per lipid [108]. Figure 2.2 shows how various q values on a scattering curve relate to
different areas in a vesicle containing sample.
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Figure 2.2: An illustration of how the scattering vector translates to different sized vesicle
features.

2.1.1

Neutron Versus X-rays
The two major types of SAS are small-angle neutron (SANS) and x-ray (SAXS)

scattering. The major difference between these two techniques is that SANS uses neutrons
as incident radiation while SAXS uses x-rays. This distinction is what makes the two techniques unique but complimentary. For SANS the incoming neutrons scatter off the nuclei
of the sample, whereas the electron cloud is the scattering medium for SAXS. For SAXS
their is a defined trend regarding how different elements interact with x-rays, as the more
electron density (ED) an element possesses the stronger it will scatter x-rays. The strength
at which an element scatters radiation can be quantified by the scattering length (SL). This
quality can be thought of as the refractive index of the element with respect to scattering.
The interaction between incident neutrons and matter is very complex, resulting in no trend
between neutron SL and the periodic table [105]. Even isotopes of the same element exude
large differences in neutron SL. Nuclei scatter incident neutrons in two ways, coherently and
incoherently. An isotope that scatters coherently scatters in a predictable manner, yielding
structural information about adjacent nuclei and itself. Contrastingly, isotopes that scatter
in an incoherent manner are unpredictable and provide little to no useful information [105].
This is an issue for biological samples as H1 nuclei scatter incoherently and compromise
some of the structural information that could be extracted from the sample. To combat

Chapter 2. Experimental Techniques

12

this deuterium, a strong coherent scatterer, is used to limit the amount of protons in the
sample and improve the quality of SANS experiments. The numerical trend difference
between ED and neutron scattering length density (NSLD) is presented in Table 2.1 [103].
Atom

H1

H2

C

N

O

Atomic Mass

1

2

12

14

16

Number of Electrons

1

1

6

7

8

NSLD, 10-12 cm

-0.374

0.667

0.665

0.940

0.580

Table 2.1: Table showing the difference in trends of electron ED and neutron SL for
nuclei commonly found in biology.

SANS and SAXS provide information regarding different structural elements of a
lipid bilayer. Considering x-rays interact with the electron density of a sample, SAXS can
be used to better locate electron rich portions of a bilayer. For membranes composed of
phospholipids this is particularly important, as phosphorus is electron rich and its location
relative to the membrane can be pinpointed. This enables parameters such as distance
between electron density maxima to be calculated [17, 104, 109]. On the other hand, SANS
can help highlight areas of the membrane with a high degree of coherent scattering. Areas
with high deuterium, carbon and/or nitrogen content scatter in a coherent manner, thus
SANS is useful locating features like the glycerol backbone and choline headgroups [17, 110–
112].
To gain complete picture regarding the framework of a lipid membrane a scattering
density profile (SDP) should be constructed. Fundamentally a SDP is the real space distribution of EDs or neutron SLs of a system. A SDP displays how the EDs and neutron SLs
fluctuate with respect to position about the bilayer. An example of this is shown in Figure
2.3, where the EDs and neutron SLs are plotted with respect to z, the distance from bilayer
center. The SDP plot allows certain portions of the lipid to be identified. For example, on
the ED side of the plot the head group region with the electron rich phosphate group can
be identified by the increase in ED around 1.5-2 nm from bilayer center.

Chapter 2. Experimental Techniques

13

Figure 2.3: A graphical comparison betweenn ED (A) and neutron SL (B) and how they
correlate to different areas of a lipid bilayer.

SANS and SAXS have been used in the past to better understand drug-membrane
interactions. These techniques can examine the impact a drug has on various biophysical
membrane parameters, such as membrane permeability and bilayer thickness, which have
cell health implications [26, 27, 109, 113]. Based on the established ability for SANS and
SAXS to effectively examine drug-membrane interactions, a similar experimental strategy
was employed during this research to better comprehend PST and its relationship with the
IMM.

2.2

Neutron Spin-Echo
Neutron spin-echo (NSE) is a neutron scattering technique that examines membrane

dynamics. It is a quasielastic technique that measures time differences that occur due to
neutron-sample interactions and through analysis this time difference can be translated to
an energetic property. In order to find variance in time the spin and magnetic moment
of the neutrons is utilized [114]. The NSE technique uses polarized neutrons, meaning all
the neutrons that enter the instrument are filtered so only neutrons of the single, desired
neutron spin orientation enter the instrument. The polarized neutrons then move through
the magnetic fields withing the NSE and eventually the detector. The key to NSE’s functionality is Larmor precession, which occurs polarized neutrons move through a magnetic
field. Larmor precession occurs when neutron spin is perpendicular to a magnetic field,
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causing the spinning neutron to rotate around the magnetic field as shown in Figure 2.4
[114]. The use of Larmor precession is the basis of NSE as it provides each neutron with
an internal clock, allowing changes in initial and final neutron velocity to be monitored and
compared [114]. The change in neutron speed as it progresses through the NSE instrument
can eventually be related to an energetic value related to the sample.

→
−
Figure 2.4: An image showing how Larmor precession occurs to a neutron spin S n in
→
−
magnetic field B .

The basic layout of a NSE instrument can be found in Figure 2.5. The rudimentary
concept is as follows [114]: The incident neutron velocity is selected for by the neutron
velocity selector (NVS). A single neutron spin state is selected via the neutron polarizer
(P). The 90◦ flipper (F) turns the polarized neutrons so their spins are perpendicular to the
magnetic field (in Figure 2.5 the magnetic field is running horizontally from left to right).
The neutrons then enter the first precession coil (PC-1), undertaking in Larmor precession.
After exiting the coil the neutrons collide with the sample (S), altering their speed and
spin direction. Following sample interaction, the neutrons are inverted by a 180◦ flipper
(F-2) and move through the second precession coil (PC-2), once again practicing Larmor
precession. The action of the neutrons moving though the second precession coil can be
though of as the neutrons unwinding their original Larmor precession in the first precession
coil, bringing the neutron’s spin back towards its original orientation. The neutrons pass
through the second 90◦ flipper (F) to stop their precession. Finally they strike the detector
(D) at a a slightly different neutron spin angle then they entered the instrument at. This
angle change is directly related to the velocity change that occurs during the neutron’s
interaction with the sample and results in a decrease in measured intensity at the detector
[114]. No angle or velocity change would be seen in the case of elastic scattering. It is also
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important to note that the NSE instrument collects information over a time period rather
than at a single moment. These different time durations are known as Fourier times.

Figure 2.5: A schematic of a NSE instrument that consists of a neutron velocity selector
(NVS), a neutron polarizer (P) two 90◦ flippers (F), magnetic precession fields (PC-1 and
PC-2) found before and following the sample (S), a 180◦ flipper (F-2) and a neutron detector
→
−
(D). Also shows how neutron spin direction S n fluctuates with respect to instrument
position for a quasielastic scattering case.

NSE can be used to effectively study membrane dynamics. An example of dynamic
membrane process that can be measured using NSE is cumulative bending and thickness
fluctuations (Figure 2.6), which bring about small changes to membrane shape [114].

Figure 2.6: An image displaying some common undulations that occur in membranes.

These changes in membrane shape have profound biological consequences on the cell and
its function. Membrane shape fluctuations play a role in protein insertion, structure maintenance and performance [13–15, 115], control of IMM functionality [116], vesicle transport
and budding [117, 118] and cell motility [119, 120]. Cancer cells have been shown to have
softer membranes then their healthy counterparts, which may have an impact on cancer
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cell movement [121, 122]. In addition to biological events, membrane dynamics has an important in understanding how drug-membrane interactions impact these biological events.
NSE has been previously used to study such interactions, finding that changes in membrane
rigidity occur due to the interaction and can be linked to certain physiological proceedings
[24, 123, 124]. Thus, NSE is a fitting technique to study how PST influences the membrane
dynamics of a model IMM.

2.3

Molecular Dynamics
Molecular dynamics (MD) is a computer simulation method used to study how both

atoms and molecules move and interact with one another. These simulations are run at
a defined temperature over a limited period of time, allowing the system to evolve over
that time span. In MD the movement of atoms and the nature of their interactions is
determined by solving Newton’s equations of motion. To solve Newton’s equations the
energetic qualities of atoms within a system must be provided by a force field. A force field
is a mathematical description of the behaviour of atoms or molecules, quantifying energies
associated with intramolecular and intermolecular forces. An example of a force field are the
Chemistry at Harvard Macromolecular Mechanics (CHARMM) force fields that are aimed
at biomolecular simulations [125, 126] and are the force fields used in the MD work for this
thesis. The CHARMM force fields are an example of all-atom force fields, meaning explicit
parameters are provided for every atom in a system. Using this type of force field in MD
can capture a high level of physical and chemical detail, but have a large computational
cost.
MD has been used in many aspects of biomembrane research. This is due to accessibility and efficiency, as many different membrane compositions can be created with relative
ease and a great deal of valuable information can be acquired [127–131]. MD has been
used to research the structural properties of membranes [132–136], membrane dynamics
[137–139], lipid domains [140], membrane-protein interactions [7, 16, 141], ion-membrane
interactions [142] and drug-membrane interactions [143]. Furthermore, MD studies have
been coupled with SANS,SAXS and NSE experiments to achieve a more comprehensive understanding of the system of interest [17, 19, 111, 144–146]. Importantly, this concept has
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been previously applied to better grasp the mechanism of bilayer-drug interactions [27, 113].
With regards to this thesis, scattering techniques in tandem with MD simulations is a powerful combination, providing useful and complimentary details regarding how PST interacts
with the model IMM.

Chapter 3

Materials and Methods
3.1

Materials

3.2

Reagents

Chloroform

Sigma-Aldrich, Oakville, ON

Deuterium Oxide

Cambridge Isotope Laboratories,
Inc., Montreal, QC

Dimethyl Sulfoxide-D6 (DMSO-d6)

Cambridge Isotope Laboratories,
Inc., Montreal, QC

Dimethyl Sulfoxide (DMSO)

Sigma-Aldrich, Oakville, ON

1-Palmitoyl-2-oleoyl-sn-glycero-3-

Avanti Polar Lipids, Inc., Alabaster,

phosphocholine (POPC)

AL, USA

1-Palmitoyl-2-oleoyl-sn-glycero-3-

Avanti Polar Lipids, Inc., Alabaster,

phosphoethanolamine (POPE)

AL, USA

Pancratistatin (PST)

Toronto Research Chemicals, North
York, ON

Tetraoleoyl cardiolipin (TOCL)

Avanti Polar Lipids, Inc., Alabaster,
AL, USA

18

Chapter 3. Materials and Methods

3.3
3.3.1

19

Methods
Experimental

Vesicle Preparation and Characterization
Lipid films were created by transferring the desired volume of lipid in chloroform
stock solution to separate glass scintillation vials using a glass syringe (Hamilton USA,
Reno, NV). Chloroform was removed from the lipid solutions under gentle house vacuum
and the resulting lipid films were dried for a minimum of 12 hours under vacuum at 30 ◦ C.
The vesicle films were then hydrated to the desired concentration with either D2 O or H2 O
depending on the experiment. The MLVs were then subjected to 5 freeze/thaw cycles at -80
◦C

and 50 ◦ C, with vortexing occurring after each thawing step. The vesicles samples were

modified into LUVs by passing the samples through a hand-held mini-extruder equipped
with 100 nm polycarbonate filters (Avanti Polar Lipids, Alabaster, AL) 31 times. LUV size
distribution was confirmed via dynamic light scattering (DLS) on a Malvern ZetaSizer Nano
ZS (Malvern Panalytical, Ltd., Malvern, UK). DLS is a technique that measures Brownian
motion and relates this to the size of a particle in solution. The diameters of the vesicles
used in various experiments can be found in Appendix A.
Three lipid species were used to create controls and the IMM mimic: tetraoleoyl cardiolipin (TOCL), 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and 1-palmitoyl2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE). Their chemical structures can be seen
below in Figure 3.1.

Figure 3.1: The chemical structure of TOCL (A), POPC (B), and POPE (C).
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These three lipid species were selected based on their relative abundance in the IMM of
eukaryotes. Lipids with a phosphocholine headgroup are the most common, followed by
lipids with a phosphoethanolamine headgroup and then cardiolipin species [42]. Hydrocarbon chains in the IMM are longer in nature and possess some degree of unsaturation.
Hence, POPC and POPE were selected as their hydrocarbon tails have both these qualities.
For cardiolipin, TOCL was selected as unsaturated 18-carbon chains account for the vast
majority of cardiolipin tails in the IMM [147, 148].
The lipids mentioned above were used to construct various vesicle compositions. The
focal composition was meant to mimic the IMM, while others served as controls to observe
if TOCL behaved differently when accompanied by only POPC or POPE. Table 3.1 shows
the mole percent of each lipid in each vesicle compositions.
Composition Name

TOCL

POPC

POPE

Analysis Methods

IMM Mimic

25

50

25

SANS, SAXS, NSE, and MD

TOCL/POPC Control

50

50

0

SANS, SAXS, NSE, and MD

TOCL/POPE Control

50

0

50

SANS, SAXS, NSE, and MD

TOCL Control

100

0

0

SANS, SAXS, and MD

Table 3.1: Table showing the relative mole percent of TOCL, POPC, and POPE in the
dissimilar vesicle compositions. Also shows the analysis techniques used on each composition.

PST Preparation and Addition
PST has very limited solubility in water [149]. Thus, PST was dissolved using
dimethyl sulfoxide-d6 (DMSO-d6) for all neutron experiments or dimethyl sulfoxide (DMSO)
for all other experiments. PST was massed out using a Sartorius Entris 64-1S Analytical
Balance (Goettingen, Germany). A concentration of 9.5

mg/mL

was achieved by adding

DMSO or DMSO-d6 to the PST powder. This concentration was used so that upon addition to the vesicle-water solution the mole percent of DMSO or DMSO-d6 was less than 1
mole percent, greatly lowing the influence of DMSO or DMSO-d6 on the structural properties of the lipid bilayer [150]. In order to fully dissolve the PST, the mixture was sonicated
at 50 ◦ C for 1 hour using a Fisherbrand CPXH 8800 Ultrasonic Water Bath (Fisher Scientific Ltd., Ottawa, ON). To ensure no PST aggregates formed, the aggregation index was
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extracted using DLS. No aggregates were observed in the DMSO or DMSO-d6 solutions.
PST was directly added to extruded vesicles at a temperature of 37 ◦ C at least 12
hours prior to any experimental analysis. This measure was taken so the time period in
which data was collected aligned with the active time period of PST based on biological
assays [37, 99]. PST was added at three mole percents: 1%, 1.5% (concentration used in
biological studies) and 2%. These concentrations are based on the approximate PST-lipid
ratio in vivo. DLS was used to ensure no PST aggregates formed upon introduction to
the vesicles or over the duration of a 24 hour experiment. At a temperature of 37 ◦ C,
time points of 0, 2, 6, 12, and 24 hours were tested. No aggregates were observed at any
time point for the DMSO or DMSO-d6 solutions. Below Table 3.2 summarizes the different
analysis methods used to analyze various combinations of vesicles compositions and PST
concentrations. SANS, SAXS, and NSE measurements were also performed on IMM mimic
vesicles in the presence of 1 volume percent DMSO or DMSO-d6 to examine if any solvent
effects existed.
Vesicle Composition

Mole% PST

Analysis Methods

IMM Mimic

1

SANS, SAXS, NSE, and MD

IMM Mimic

1.5

SANS, SAXS, NSE, and MD

IMM Mimic

2

SANS, SAXS, NSE, and MD

TOCL/POPC Control

1

SANS, SAXS, NSE, and MD

TOCL/POPC Control

2

SAXS and MD

TOCL/POPE Control

1

SANS, SAXS, NSE, and MD

TOCL/POPE Control

2

SAXS, NSE, and MD

Table 3.2: Table showing the techniques used to analyze IMM, TOCL/POPC control,
and the TOCL/POPE control with repect to PST mole percent.

SANS Measurements
SANS measurements were conducted on the NGB 30 m SANS instrument located at
the National Institute of Standards and Technology Center for Neutron Research (NCNR,
Gaithersburg, MD)[151]. Neutrons with a wavelength of 6 Å were used, as well as two
sample-to-detector distances (1.33 m and 4 m), to access a scattering vector range of approx-
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mg/mL

in D2 O were loaded

into 1 mm path-length quartz banjo cells (Hellma USA, Plainsview, NY) and mounted in a
Peltier temperature- controlled cell holder with ≈ 1◦ C accuracy. The scattered beam was
counted on a 2D 3 He detector and subsequently radially-averaged, stitched, and corrected
for background scattering from D2 O (SANS measurements showed no major differences in
scattering between pure D2 O and D2 O with 1 vol% DMSO-d6, shown in Figure A.12) using
Igor Pro and the appropriate macros provided by NCNR [152]. As a result, 1D scattering
curves of total intensity against the scattering vector (I vs. q) were produced. The SANS
data was analyzed used vesicle viewer software [153]. All measurements were collected at
37 ◦ C.

SAXS Measurements
SAXS experiments were carried using the 12-ID-B beamline at the Advanced Photon
Source (Argonne National Laboratory, Lemont, IL). An average photon energy of 13.3 keV
was used and data was collected using 2M Pilatus detector (Dectris Ltd., Philadelphia,
PA) set at a sample-distance of 2.0106 m. X-rays with a wavelength of 0.9322 Å were
used. The resulting form factors in the scattering vector range of 0.03 Å−1 < q < 0.9 Å−1
were background corrected using the established on-site reduction workflow and analyzed
using vesicle viewer software [153]. All measurements were collected at 37 ◦ C. LUVs at a
concentration of 15

mg/mL

in H2 O were loaded into temperature controlled capillary cells.

These cells oscillated ∼100 µL of sample to avoid ionization damage.

Neutron Spin-Echo Spectroscopy
Data was collected on the NG-A NSE spectrometer at the NCNR [154]. Neutron
wavelengths of 8 Å and 11 Å were used to obtain a momentum transfer range of 0.045 Å−1 <
q < 0.1 Å−1 . Fourier times of up to 100 ns were employed, allowing bilayer motions on length
scales of ≈0.1 nm to 10 nm and time scales of 0.1 ns to 100 ns. LUVs at a concentration of
10 mg/mL in D2 O were loaded into cells with a 4 mm path length for the NSE measurements.
All samples were measured at 37 ◦ C. Samples were allowed to temperature equilibrate for 30
minutes prior to evaluation, the temperature was maintained within ≈0.5 ◦ C. The resulting
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NSE data was reduced using the Data Analysis and Visualization Environment (DAVE)
software package [155].

3.3.2

Computational
Atomistic MD simulations were performed using the GROMACS 2018.3 package

[156] and the CHARMM36 force field [126]. The CHARMM PST force field was generously
provided by Markus Miettinen from the Max Planck Institute for Colloids and Interfaces.
The PST molecules were placed on one side of the membrane to be consistent with physical
tests as PST was added externally during those experiments. Prior to the production
runs for the PST containing membranes, multiple small simulation runs (20 ns each) were
executed to bring the PST molecules closer to the membrane. All membrane compositions
were generated using the CHARMM-GUI input generator [131]. The composition of all the
vesicle systems used in simulations and total simulation time can be seen in Table 3.3.
Number of Molecules
Composition

Simulation Time (ns)
TOCL

POPC

POPE

H2 O

Na+

PST

IMM Mimic

570

30

60

30

9000

60

0

IMM Mimic w/ 1% PST

560

30

60

30

8987

60

1

IMM Mimic w/ 1.5% PST

570

30

60

30

8971

60

2

IMM Mimic w/ 2% PST

550

30

60

30

8955

60

3

TOCL/POPC Control

540

60

60

0

12000

120

0

TOCL/POPC w/ 1% PST

530

60

60

0

11984

120

1

TOCL/POPC w/ 2% PST

550

60

60

0

11955

120

3

TOCL/POPE Control

530

60

0

60

12000

120

0

TOCL/POPE w/ 1% PST

560

60

0

60

11982

120

1

TOCL/POPE w/ 2% PST

560

60

0

60

11957

120

3

TOCL Control

560

90

0

0

13500

180

0

Table 3.3: Table showing simulation time and the amount of lipid species, water, sodium,
and PST present in each vesicle compositions used for MD simulations.

Energy minimization and equilibration steps were performed according to the CHARMM-
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GUI guidelines. The energy minimization began with steepest-descent minimization for
5000 steps followed by ensemble equilibration for 50 ps with a timestep of 1 fs, followed
by isothermal-isobaric ensemble equilibration for 325 ps at a timestep of 2 fs, with semiisotropic pressure coupling accomplished using the Berendsen barostat [157]. Equilibration
was monitored by observing the system’s area per lipid.
Unconstrained MD simulations were run for over 500 ns for each composition using
a timestep of 2 fs. All simulations were kept at 37 ◦ C using velocity-rescaling temperature
coupling [158]. Pressure coupling was applied using the Parrinello-Rahman barostat [159].
A zero surface tension ensemble was created by setting a reference pressure of 1 bar for
both the bilayer plane and the normal to the bilayer. Bilayer compressibility was set to
0.000045 bar−1 . Van der Waals interactions were cut off at 1.2 nm, and the interactions were
modified using the force-switch method between 1.0 and 1.2 nm. Long-range electrostatics
were determined using the particle mesh Ewald (PME) method, with a cutoff of 1.2 nm. The
final 500 ns of the unrestrained MD simulations was used for data analysis. A combination of
in-house scripts, GROMACS tools, and the Visual Molecular Dynamics (VMD) 1.9 program
[160] were used to analyze the simulations. All errors were estimated using cumulative
averaging.

Chapter 4

Results
4.1

Bilayer Structure
SANS and SAXS are proven techniques capable of resolving bilayer structure [161,

162]. To quantify structural data from SAS the raw form factor must be modeled. The
model used was a modified SDP model where SANS and SAXS data can be jointly analyzed,
as shown in Figure 4.1 pertaining to data from the IMM mimic LUVs. The SDP model
was previously eluded to in Section 2.1.1. SDP models are generated from the volume
probabilities of membrane components (Figure 4.1E), which describes the likelihood of
finding a specific membrane components at some distance from the bilayer center. The
volume probability of each component is scaled to the electron quantity and neutron SL of
that components to generate ED (Figure 4.1C) and NSLD (Figure 4.1D) profiles [19]. The
Fourier transform of the resulting ED and NSLD profile yields a form factor that can be
compared to the raw form factor to accurately model and refine the data [19, 146, 163].
The optimized models for the SANS and SAXS data from the IMM mimic can be seen in
Figure 4.1A-B. For all other compositions analyzed using SANS and/or SAXS, their form
factors and corresponding fits can be found in Appendix A.
The SDP model used in the SANS and SAXS analysis parses the lipid membranes into
3 different components. The hydrocarbon chains were divided into two groups: the terminal
methyl (CH3 , pink Gaussian in Figure 4.1C-E) and the rest of the hydrocarbon chain
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(CH2 CH, green Gaussian in Figure 4.1C-E). The headgroup region is the final grouping,
it contains all remaining components of the lipid outside of the hydrocarbon chains (red
Gaussian in Figure 4.1C-E). Water distribution (blue lines in Figure 4.1C-E) and combined
SDP (grey lines in Figure 4.1C-E) are also described in the SDP model. The combined
SDP calculated from MD simulations of the IMM mimic (purple lines in Figure 4.1C-E) are
provided for a visual comparison between MD and SAS.

Figure 4.1: SANS (A) and SAXS (B) form factors with their corresponding SDP model
fits (solid lines) for the IMM mimic LUVs. The SDP models of the IMM mimic LUVs are
displayed in the upper-right panel, where the ED (C) is on the left half and the NSLD (D)
is on the right half. The volume probability distribution is displayed in the bottom right
panel (E), where the total probability is equal to 1 at each point along the bilayer normal.

A multitude of structural bilayer characteristics can be found using the SDP analysis
model. Area per lipid (AL ) is an important parameter that can be extracted from analyzing
SAS data. AL is defined as the membrane surface area occupied by a lipid. Three types
of membrane thicknesses were derived from the SAS data: Luzzati bilayer thickness (DB ),
headgroup-to-headgroup distance (DHH ), and hydrocarbon thickness (2DC ). DB is also
known as the Gibbs dividing surface and can be described as the point along the bilayer
normal at which the probability of finding a water and not finding a water is equal [164].
DHH is described as the distance between electron density maxima, i.e. the distance between
the electron-rich phosphorus atoms. 2DC is defined as the distance between the sn-2 glycerol
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carbons as this is the starting point of the acyl chains. A graphical representation of DB ,
DHH , and 2DC can be found in 4.1E and their values from SDP analysis can be found in
Table 4.1. Crucially, AL , DB , DHH , and 2DC have proven to be an important parameters
when looking at drug-membrane interactions [24, 26, 27, 109, 124].
Computationally, the structural parameters where calculated using GROMACS tools.
Firstly, AL was found by simply dividing the surface area covered by the bilayer in the XYplane by the number of lipids in the XY-plane (see Figure 4.2).

Figure 4.2: A bird’s eye view of a lipid bilayer to show how AL is extracted from MD
simulations.

In order to find DB the density profile of water in the simulations was found using gmx
density. The point where the area underneath and above the water density curve is equal
corresponds to DB , as shown by the green shaded sections in Figure 4.3.

Figure 4.3: A visualization of how the densities of different bilayer components correlates to various types of membrane thicknesses, as shown using data from the IMM mimic
simulation run. The density of water is represented by the blue line and corresponds to
DB (distance between dashed black lines), the density of phosphorus is represented by the
purple line and corresponds to DHH (distance between dashed purple lines), and the density
of sn-2 is represented by the red line and corresponds to 2DC (distance between dashed
red lines).
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By definition, this is the point where the probability of finding a water molecule and not
finding a water molecule is equal. Finding DHH and 2DC requires a density profile to be
made for the phosphorus atoms and the sn-2 carbon atoms respectively, as shown in Figure
4.3. Finding the distance between the maximum values of the density plot on each side of
the bilayer will generate DHH and 2DC . The values of AL , DB , DHH , and 2DC generated
from MD simulations can be found in Table 4.1.
Vesicle Composition

AL (Å2 )

DB (Å)

DHH (Å)

2DC (Å)

IMM Mimic (SAS)

80.9 ±0.2

40.6 ±0.5

41 ±0.5

31.3 ±0.4

IMM Mimic w/ 1% PST (SAS)

79.8 ±0.3

40.9 ±0.5

41.1 ±0.3

31.2 ±0.2

IMM Mimic w/ 1.5% PST (SAS)

79.4 ±0.4

41.3 ±0.2

41.6 ±0.4

31.9 ±0.3

IMM Mimic w/ 2% PST (SAS)

78.2 ±0.3

41.7 ±0.3

42.1 ±0.3

32.6 ±0.2

IMM Mimic w/ DMSO-d6 (SAS)

80.3 ±0.2

40.7 ±0.5

41.1 ±0.7

31.6 ±0.4

IMM Mimic (MD)

79.3 ±0.1

41 ±0.1

41.5 ±0.1

31.9 ±0.05

IMM Mimic w/ 1% PST (MD)

79.1 ±0.1

41.6 ±0.1

41.6 ±0.1

32.1 ±0.1

IMM Mimic w/ 1.5% PST (MD)

78.8 ±0.05

41.9 ±0.1

42.3 ±0.1

32.2 ±0.1

IMM Mimic w/ 2% PST (MD)

78.4 ±0.1

42.8 ±0.1

42.8 ±0.3

32.7 ±0.1

TOCL/POPC Control (SAS)

97.9 ±0.4

38 ±0.3

40.1 ±0.5

29.8 ±0.2

TOCL/POPC w/ 1% PST (SAS)

96.7 ±0.3

38.3 ±0.5

40.2 ±0.4

30.1 ±0.3

TOCL/POPC w/ 2% PST (SAS)

96.5 ±0.2

38.9 ±0.6

40.7 ±0.4

30.7 ±0.2

TOCL/POPC Control (MD)

97.6 ±0.05

37.1 ±0.05

39.9 ±0.1

29.2 ±0.1

TOCL/POPC w/ 1% PST (MD)

97.3 ±0.1

37.7 ±0.2

40.2 ±0.1

29.4 ±0.1

TOCL/POPC w/ 2% PST (MD)

97.2 ±0.1

37.7 ±0.05

40.3 ±0.1

29.7 ±0.1

TOCL/POPE Control (SAS)

95.9 ±0.1

35.9 ±0.2

39.4 ±0.4

29.7 ±0.3

TOCL/POPE w/ 1% PST (SAS)

95.6 ±0.2

36.3 ±0.4

39.6 ±0.3

30 ±0.3

TOCL/POPE w/ 2% PST (SAS)

94.7 ±0.4

36.5 ±0.1

40.0 ±0.3

30.2 ±0.2

TOCL/POPE Control (MD)

94.7 ±0.1

36.7 ±0.1

40 ±0.1

30.2 ±0.1

TOCL/POPE w/ 1% PST (MD)

94.3 ±0.1

36.9 ±0.1

40.4 ±0.1

30.7 ±0.1

TOCL/POPE w/ 2% PST (MD)

94.4 ±0.05

37.1 ±0.1

40.3 ±0.1

30.6 ±0.05

TOCL Control (SAS)

130.2 ±0.3

36.8 ±0.6

39.4 ±0.4

29.2 ±0.3

TOCL Control (MD)

132.2 ±0.1

36.6 ±0.1

39.1 ±0.2

29.1 ±0.1

Table 4.1: Structural parameters of various compositions generated from SDP model
analysis and unrestrained MD simulations.
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The AL and thickness values from the SAS experiments and MD simulations are
similar, as outlined in Table 4.1. This is also shown in Figure 4.1C-E, as the SDP models
generated from SAS and MD are alike. This result displays the validity of the MD simulations. Furthermore, the AL and thickness results agree with studies previously performed
on pure TOCL bilayers [17, 136]. As for the other compositions, very little structural data
has been reported in literature. A MD study recently reported DHH values from compositions similar to the IMM mimic, the POPC/TOCL control and the POPE/TOCL control;
the DHH values agreed well with values reported in this thesis [134]. The AL for the mixed
compositions fall between the AL values of TOCL and the AL values of pure POPC [165]
and/or POPE [23] bilayers. Two trends can be seen in Table 4.1: a decrease in AL and an
increase in membrane thickness. Aside from TOCL/POPE w/ 2% PST, every composition
follows the PST dependant tendencies. These trends are visually represented in Figure 4.4,
where structural data pertaining to the IMM mimic is plotted. Based on these findings,
PST influences membrane structure properties. Possible explanations for these changes in
AL and membrane thickness will be discussed in Chapter 5.

Figure 4.4: Graphs comparing structural data extracted from SAS (A) and MD simulations (B) of the IMM mimic with 0, 1, 1.5, and 2 mol% PST. Four parameters are shown:
AL , DB , DHH , and 2DC .

4.2

Membrane Rigidity
NSE measurements were performed to determine membrane bending rigidity with

respect to PST concentration. The compositions mentioned in Tables 3.1 and 3.2 were used
in the NSE experiments. NSE data were plotted using normalized intermediate scattering
functions,

I (Q,t)/I (Q,0),

which extract information regarding membrane undulations. Using
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the IMM mimic results as an example, when Fourier time is plotted against the intermediate
scattering function it follows a stretched exponential (see Figure 4.5A) as predicted by
Zilman and Granek for bilayer bending fluctuations where the bilayer is treated as a thin
elastic sheet [114, 166] and defined as,

2/3
I (Q, t)
2
' e −DQ t e −(ΓZG t) .
I (Q, 0 )

(4.2.1)

In Equation 4.2.1, Q is the scattering vector, t is the Fourier time and D is the StokesEinstein diffusion coefficient (D =

kB T/6πηR )

and is dependant on the hydrodynamic radius

of the vesicle, R, solvent viscosity, η, absolute temperature, T, and kB as the Boltzmann
constant. As outlined by Hoffman et al. [167], D is a correction factor applied to account
for contributions from vesicle diffusion. The hydrodynamic radii of the vesicles and their D
values can be found in Table 4.2.
Vesicle Composition

Radius (nm)

D (Å2/ns)

IMM Mimic

69 ±4.6

0.394

IMM Mimic w/ 1% PST

69.2 ±4.1

0.393

IMM Mimic w/ 1.5% PST

68.4 ±4

0.397

IMM Mimic w/ 2% PST

69.3 ±4.7

0.392

IMM Mimic w/ DMSO-d6

68.5 ±5.1

0.396

TOCL/POPC Control

68.2 ±4.4

0.398

TOCL/POPC w/ 1% PST

69 ±4.9

0.394

TOCL/POPE Control

60.1 ±3.2

0.452

TOCL/POPE w/ 1% PST

59.7 ±3.1

0.455

TOCL/POPE w/ 2% PST

61.2 ±4.1

0.442

Table 4.2: Vesicle radii and corresponding Stokes-Einstein diffusion coefficients for the
NSE samples.

Exponential fits with Equation 4.2.1 are displayed as solid lines in Figure 4.5A. From
these fits the decay rates, ΓZG , were obtained. The decay rates follow the predicted linear
dependency when plotted against Q3 (see Figure 4.5B), where the slope is inversely related
to the effective membrane bending modulus, κ
e [166]. Watson and Brown extended on the
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work of Zilman and Granek by accounting for the notable thickness and internal dissipation
of a bilayer, which cannot be accurately described as a thin elastic sheet [168, 169]. They
demonstrated that κ
e measured by NSE is related to the intrinsic bending modulus, κ,
through

κ
e = κ + 2d 2 κm

(4.2.2)

where d describes the height of the neutral surface from the bilayers midplane (hypothesized
to be 0.5) [114, 170] and κm is the monolayer compressibility modulus.

Figure 4.5: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by NSE
(A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B) for the
IMM mimic. Error bars represent one standard deviation.

The Zilman-Granek and Watson-Brown theories were be used in conjunction to
extract κ from the plot of ΓZG versus Q3 (Figure 4.5B) by [170]

r
kb T kb T
ΓZG
.
= 0.0069
3
Q
κ η

(4.2.3)

Equation 4.2.3 shows the inverse relationship between ΓZG and κ: a stiffer membrane will
have a larger κ and a faster decay rate when compared to a softer membrane, which will
have a smaller κ and a slower decay rate [114]. The κ results for the NSE experiments are
shown in Table 4.3. The

I (Q,t)/I (Q,0)

curves and ΓZG versus Q3 plots for all samples aside
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from the IMM mimic can be found in Appendix B.
The bending rigidity of the MD simulations was determined using a computational
methodology created by Doktorova and colleagues [138]. This technique analyses fluctuations in the lipid membranes and has generated values similar to those found using NSE on
unsaturated lipid systems [138]. Using a distance cutoff of 14 Å to restrict the calculation
to adjacent lipids, κ was analyzed by determining how neighbouring lipids interact with
one another and how these interactions effect membrane undulations. The κ from the MD
simulations can be seen in Table 4.3.
Composition

κ(kB T )
NSE

MD

IMM Mimic

28 ±0.9

33.4 ±0.7

IMM Mimic w/ 1% PST

31.4 ±1

36.4 ±0.6

IMM Mimic w/ 1.5% PST

34.9 ±0.97

37.6 ±0.6

IMM Mimic w/ 2% PST

44.1 ±1.9

39.8 ±0.6

IMM Mimic w/ DMSO-d6

30.8 ±0.8

—

TOCL/POPC Control

30.8 ±0.6

31.2 ±0.6

TOCL/POPC w/ 1% PST

39.8 ±1.7

34.3 ±0.6

TOCL/POPC w/ 2% PST

—

36.3 ±0.6

TOCL/POPE Control

26.9 ±1

30.1 ±0.7

TOCL/POPE w/ 1% PST

29.9 ±0.8

32.8 ±0.5

TOCL/POPE w/ 2% PST

37.7 ±1.9

33.9 ±0.6

TOCL Control

—

30.5 ±0.8

Table 4.3: Bending modulus κ of various compositions found using NSE and/or MD
simulations.

Aside from the TOCL control, the bending moduli for all other compositions have
yet to be reported in literature. Thus, direct comparison with previous studies regarding κ
is not possible. However, certain conclusions can be drawn. When compared to previous
work on pure POPC and POPE bilayers, membrane order is increased by the presence of
TOCL [23, 171, 172]. Additionally, CL has been shown to increase κ in PC membranes
[173]. An increase in membrane order will make the bilayer more compact, leading to a
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larger κ value. Ordered domains within CL containing membranes have been shown in
numerous studies, including studies on mixtures that include the main lipid constituents
of the IMM [174], as well as bilayers composed of PE/CL [175–178]. Domains have not
been reported in PC/CL membranes, but it is hypothesized that a superlattice structures
exist [133, 179]. Our results follow this trend in that κ and the relative amount of CL
are correlated. Additionally, the solvent effects of DMSO-d6 appear to be minimal. The
inclusion of PST has a notably larger impact on κ than DMSO-d6 alone. This points to
PST as the major influence on membrane stiffness, but the possibility of DMSO-d6 still
acting as a chaperon for PST cannot be entirely dismissed.
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Figure 4.6: Decay rate ΓZG normalized by Q3 for all Q for the IMM mimic, POPC/TOCL
and POPE/TOCL samples with respect to PST concentration (A). Bending moduli (κ) for
all samples with increasing amounts of PST measured by NSE and MD simulations (B).
Note that the IMM mimic with DMSO-d6 (* in plot B) does not contain PST, but contains
the volume of DMSO-d6 necessary to deliver 2 mol% PST.

The effect of PST is apparent when examining the decay rates and κ values. As
previously eluded to, the decay rate and κ are inversely related. This is shown in Figure
4.6. In Figure 4.6A a decrease in

ΓZG/Q3

directly corresponds to an increase in κ as shown

in 4.6B. Evidently, PST is stiffening the membrane and increasing κ for all compositions
tested. This is true for both the NSE and MD experiments. It is also worth noting that
PST makes the lipid bilayer more rigid regardless of composition.
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Hydrocarbon Chain Order
The acyl chain order parameter (SCH ) was calculated from MD simulations to ex-

amine the impact of PST on membrane fluidity. SCH provides information regarding the
flexibility of the hydrocarbon chains, which has proven useful for understanding membrane
phase behaviour [133, 180] and membrane interactions with drugs and other biomolecules
[27, 181, 182]. SCH is calculated by

3
1
SCH = hcos2 θi − ,
2
2

(4.3.1)

where θ is the angle between the C-H bond vector and the bilayer normal. This equation
describes the orientation of the C-H bonds in the acyl chains with respect to the bilayer
normal averaged for all chains of a particular lipid over the sampling duration [183]. The
magnitude of SCH is directly related to acyl chain order, meaning a more ordered hydrocarbon chain will have a higher SCH and vice versa.
The SCH values were calculated for the sn-1 and sn-2 chains for all lipid species in
each composition. The sn-1 and sn-2 chain length and degree of saturation varied with
composition. TOCL only contains oleoyl chains (18:1), while POPC and POPE have a
palmitoyl chain (16:0) in the sn-1 position and an oleoyl chain in the sn-2 position. It
should be noted that the SCH values reported for the sn-1 and sn-2 chains of TOCL are the
averages of the findings from the two sn-1 and two sn-2 chains. The difference in saturation
is visible in the SCH plots in Figure 4.7, as double bonds are well known to encourage
disorder. Figure 4.7 also displays PST’s influence on the IMM mimic. A comparison of SCH
values between the 0, 1, 1.5, and 2 mol% PST for both the sn-1 and sn-2 chains of each
lipid in the IMM mimic composition can be observed in 4.7. Furthermore, similar plots can
be found in Appendix C for all other compositions.
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Figure 4.7: Acyl chain order parameters extracted from MD simulations of the IMM
mimic with 0, 1, 1.5, and 2 mol% PST. Order parameters (SCH ) throughout the length of
the sn-1 (A, C, and E) and sn-2 (B, D, and F) acyl chains are shown for the lipids that
compose the IMM mimic: TOCL (A and B), POPC (C and D), and POPE (E and F).

Firstly, the trend in SCH values found for all compositions is similar to those previously reported in literature [133, 135, 136, 184–186]. The SCH results indicate that carbons
closer to the glycerol backbone are more susceptible to ordering by PST, as shown by the
increase in SCH from 0 to 2 mol% PST. This is most evident in the TOCL SCH values
between C2-C8 for both the sn-1 and sn-2 chains. PST enforces the same trends mentioned above on the POPC/TOCL and POPE/TOCL controls (see Appendix C. Moreover,
this trend appears to be more obvious for the POPC/TOCL and POPE/TOCL controls,
possibly caused by the higher concentration of TOCL present in those compositions. The
increase in acyl chain order provides an explanation to the climbing κ values shown in Section 4.2, as a more ordered membrane would be stiffer. PST appears to have little to no
impact on the chain order as the proximity to bilayer center decreases. This points to PST
interacting with the headgroup region of the lipid, which corroborates with the thickness
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and AL changes described Section 4.1.

4.4

PST Localization
The location of PST relative to the lipid bilayer was found for various MD simulations.

Finding where drugs sit in relation to the membrane is key to understanding how they
influence membrane properties, and consequently biological events [24, 26–28, 109, 124, 187].
To find where PST localizes the density of PST was averaged over final 500 ns of each
simulation containing PST. It should be noted that PST density is plotted against the
distance from bilayer center, but only for the half of the membrane where the PST molecules
were placed to be consistent with experimental procedure. An example of a PST density
profile is shown in Figure 4.8, where the density of PST is plotted against distance from
bilayer center. The PST density profiles from the IMM bilayers is shown in Figure 4.8,
while the PST density profiles for all other compositions can be found in Appendix D.

Figure 4.8: PST density profiles extracted from MD runs of the IMM mimic bilayers in
the presence of 1, 1.5, and 2 mol% PST. The numbers inserted at the maximum amplitude
of each curve correspond to the distance from bilayer center at which the maximum value
occurs.

Based on the PST density profiles, it can be concluded that PST is concentrated on
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the surface of the membrane. The maximum PST density for all simulations are between
21-23 Å, falling only slightly outside the DB and DHH values reported in Table 4.1 if they
were cut in half. This demonstrates that PST localizes at the membrane surface regardless
of composition. This results clearly shows that PST has a stronger affinity to the membrane
than the surrounding water, which is logical due to PST’s lack of solubility in water [149].
Also, visual examination of the simulations showed that PST did not cross the membrane.
The position of PST relative to the membrane supports results found in Section 4.2, which
will be discussed in Chapter 5.

4.5

PST’s Lipid Preference
The lipid favouritism of PST was investigated to using MD simulations. Recent

studies have shown that some molecular therapeutics associate more with specific lipid
species [28, 187], which could impact biological processes where that lipid species plays
a valuable role. To determine if PST has a lipid bias the radial distribution function
(RDF), g(r), between PST and each lipid species in a membrane was computed for all PST
containing simulations. The RDF describes the how the density of a defined portion of
matter changes as a function of distance from a point. During MD simulations, PST was
inserted into the solvent in a random manner. Therefore, if PST closely associates with
a particular lipid species, that lipid species is likely significant to PST’s functionality and
interacts with PST in a more favourable manner than the other lipids.
In order to calculate the RDF two molecules or points within two molecules must be
specified. In the case of this thesis, the center of mass of both PST and the headgroup of
the chosen lipid species was used. The lipid headgroup was defined as the functional groups
attached to the sn-3 carbon of the glycerol chain. For TOCL, this included the glycerol
bridge connecting the two phosphate groups. After defining the two groups of interest, the
RDF was calculated over the duration of each simulation, resulting in a plot of g(r) versus
distance. These graphs show the density of a specific lipid headgroup changes over certain
distance from a PST molecule. RDF plots can be found in Figure 4.9A-C for all PST
containing simulations on the IMM mimic composition. The RDFs for the POPC/TOCL
and POPE/TOCL controls with 1 and 2 mol% PST can be found in Appendix E.
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Figure 4.9: RDF graphs for MD simulations corresponding to the IMM mimic with 1
(A), 1.5 (B), and 2 (C) mol% PST. The bottom-right panel (D) shows a cartoon of PST
more closely associating itself with TOCL rather than other present lipid species.

The results from the RDFs show that PST has a clear inclination to associate with
TOCL over POPC or POPE. In Figure 4.9A-C it is clear that the number of TOCL headgroups is greater than the other lipids when in close proximity to PST. This finding is
especially notable considering TOCL only accounts for 25 mol% of the IMM mimic. Therefore, TOCL must have a momentous interaction with PST in order to draw PST away
from the only lipid species occupying the remaining 75 mol% of the IMM mimic. Figure
4.9D provides a cartoon depiction on how PST tends to localize near area of high TOCL
concentration. Essentially, PST sits near the surface of the membrane that is occupied by a
high number of TOCL lipids. This suggests that TOCL rafts or domains are forming either
prior to interacting with PST or as a result of the PST-TOCL dynamic.
To further investigate the possibility of TOCL domains existing before or as a result of
PST addition, the RDFs between lipid species in the IMM mimic simulations was assessed.
These RDF plots are shown in Figure 4.10, where a higher g(r) value at a smaller distance
indicates that the chosen lipid species are closer to each other in the membrane. Figure
4.10 show the RDF plots for POPC and POPE in relation to TOCL, as well as the RDF
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for TOCL with other TOCL molecules, at each PST concentration. Based on 4.10, TOCL
lies closest to other TOCL lipids, regardless of PST concentration. Considering TOCL only
accounts for 25 mol% of the membrane, its evident that TOCL molecules have an inclination
towards other TOCL molecules. This indicates that TOCL may form an ordered domain
before PST is added and not as a result of PST’s introduction. Considering PST has a high
affinity for TOCL, its possible that TOCL domains could be a target for PST. This idea
and its biological repercussions will be further discussed in Chapter 5.

Figure 4.10: RDF graphs for MD simulations corresponding to the IMM mimic with 0
(A), 1 (B), 1.5 (C), and 2 (D) mol% PST. These plots examine the distance between the
different lipid species as more PST is added to the system.

The association of PST with TOCL is more evident in the POPC/TOCL (Figure E.1)
and POPC/TOCL (Figure E.2) controls. This is likely due to the higher concentration of
TOCL, as TOCL would cover a larger surface area and be more readily available to interact
with PST. However, the affinity between PST and TOCL is still evident as it clearly interacts
more than with POPC or POPE at an equal concentration. When comparing the RDFs of
POPC and POPE its noticeable that POPE has a stronger inclination towards PST than
POPC (see Figures 4.9A-C, E.1, and E.2. This is a noteworthy finding considering the IMM

Chapter 4. Results

41

mimic only contains 25 mol% POPE.
It should also be noted that the hydrogen bonding of each lipid species with PST was
examined to determine if hydrogen bonding was the reason behind PST’s affinity to TOCL.
It was determined that PST showed very little hydrogen bonding with lipid headgroups.
Furthermore, the small amount of hydrogen bonding that did occur was evenly distributed
between the different headgroups, where the number of hydrogen bonds per lipid with PST
ranged between 0.02-0.04. This points out that hydrogen bonding is unlikely responsible
for PST’s attracting to TOCL.

Chapter 5

Discussion
5.1

PST’s Impact on Membrane Stiffness and Structure
Anti-cancer drugs have previously shown condensing effects on lipid bilayers [188–

190]. These studies pointed to a drug-headgroup interaction as the source of the condensing
effect. A similar outcome is seen when PST interacts with lipid bilayers, where rigidity
increases, AL decreases, and bilayer thickness increases, all of which are signs of a more
ordered membrane. A possible explanation for these effects is that PST sits directly on
top of the lipid headgroups. When unaccompanied by PST, the membrane is free to bend
without restriction. When PST is present it acts as a physical obstruction that interferes
with membrane undulations (see Figure 5.1), consequently causing an increase in κ.

Figure 5.1: Illustration of how PST sits on the surface of the lipid bilayer, dampening
membrane bending fluctuations by condensing the membrane.
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The observed dampening effect can be explained by PST acting as a anchoring point on the
bilayer sheet. The PST anchors dampen longer wavelength modes of the bilayer bending
resulting in an overall stiffening of the bilayer. This explanation is supported by the distribution of PST from MD A possible implication of PST stiffening the IMM in cancerous
mitochondria will be explored in Section 5.4.
Like cholesterol, PST is a molecule that condenses fluid membranes by creating more
ordered phases [172, 180, 191]. Although both PST and cholesterol are order inducing
agents, that is where their similarities end. Cholesterol inserts into a fluid membrane,
where through hydrogen-bonding with phospholipids it causes bilayer condensation [172].
In contrast, results reported in this thesis show that PST does not enter the membrane,
instead impacting membrane dynamics via surface interactions. Interestingly, PST appears
to increase κ more than cholesterol at a smaller mol% [172]. However, PST appears to
be lipid selective, while cholesterol effects a much broader range of lipids, displaying both
ordering and disordering effects [180].
The variation in κ between the compositions examined with NSE and MD can be
explained by considering that POPC and POPE may interact with CL in different ways.
PC/CL membranes have not demonstrated the ability to form domains, but the idea that
they form ordered superlattices has been proposed [179]. PE/CL membranes on the other
hand are heavily linked with CL domain formation [175–178]. Although domains and superlattices are ordered, both are transient and dispersed randomly across the membrane,
making them difficult to detect. It’s possible that a POPC/TOCL superlattice may account
for the higher κ values when compared to the POPE/TOCL domains, simply due to superlattices forming more often. This is feasible considering the formation of a superlattice is
energetically favourable [179].
As previously stated, the structural parameters found from SAS and MD show that
PST is condensing the membrane. As a membrane is condensed its thickness increases due
to tighter lipid packing, which consequently results in a decrease in AL . The structural
parameters varied with PST concentration in a linear fashion. A similar trend was recently
reported regarding the condensation of POPC membranes by carotenoids [192]. Considering
no plateau was reached regarding the effect of PST on membrane structure, its possible that
a higher dose of PST could further change membrane properties. However, it should be
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stated that the quantities of PST examined here have shown efficacy [36, 37, 101, 102].

5.2

Bilayer Organization
Using both experimental and computational methods, lateral heterogeneity has been

reported in membranes containing CL, PE and PC lipids [64, 174–179]. In these studies CL
forms the ordered domain, while the other lipids are found in a less ordered state. These
CL rafts are important for the function of membrane associated proteins, including portion
of the ETC [3, 20]. The exact driving force of CL segregation is not entirely understood,
as some recent literature has pointed that CL does not form domains, but simply localizes
in area of high curvature due to its considerable negative curvature [193]. Regardless, both
conjectures point to CL segregation in some manner. Results reported in this thesis suggest
that TOCL localization may exist in the tested membrane compositions and are effected by
PST. Firstly, the results from the RDF calculations (Figure 4.10) indicate that TOCLs lie
closer to each other than POPC and POPE, and this does not change when PST is present.
This supports that TOCL-heavy areas may form in the presence of POPC and POPE,
but this is far from conclusive. This result is not direct evidence of domain formation, as
techniques such as fluorescence microscopy and contrast-matched SANS, are required to
confirm the presence of lipid rafts [194–196]. However, it is still notable that the membrane
simulations of the IMM mimic show that TOCL lipids have a degree of lateral organization
that is maintained throughout the addition of PST and not caused by the addition of PST.
Furthermore, it points out that domain disruption is an unlikely method of action for PST.

5.3

Membrane Order and PST’s Affinity to Cardiolipin
Interestingly, PST induces membrane order. This occurs consistently as PST concen-

tration increases for all compositions, and is shown by the increase in chain order, increase
in κ, and changes in structural parameters. More specifically, PST increases the order of
TOCL carbons close to the headgroup. Based on this finding, PST targets areas of the
membrane where TOCL is abundant and condenses the membrane by interacting with the
headgroups of TOCL. Although the condensing effect of PST is evident, the nature of its

Chapter 5. Discussion

45

interaction with TOCL remains unclear.
Based on the analysis of the MD simulation, hydrogen bonding is not the cause of
the PST-TOCL relationship. The unique shape of CL lipids provides a possible explanation
for the affinity between PST and TOCL. As discussed in Chapter 1, CL lacks the shielding
characteristics of other lipids, leaving the negative charge of their headgroup open to the
aqueous environment and available for electrostatic interactions [66, 67]. Previous work
has noted that CL’s bonding tendencies are not fully understood, but evidence shows that
CL binds to proteins in a non-selective and ionic fashion, while peripheral protein seek out
CL over other phospholipids [197–199]. Considering CL binds to proteins in a non-specific
fashion, its possible PST binds to CL in a similar manner. TOCL’s exposed headgroup may
provides a binding opportunity to PST, explaining PST’s affinity to TOCL.

5.4

Possible Apoptotic Consequences
Due to the high proliferation rate and energetic needs of cancer cells, many can-

cers turn to oxidative phosphorylation and aerobic respiration in tandem to meet energy
requirements [87–92]. This presents the ETC as a target for anti-cancer drug therapies, as
the various protein complexes can be targeted to disrupt the chain [77, 87]. One way PST
could target the ETC is by changing the fluidity of the IMM and by limiting the capabilities
of CL. Literature has shown that CL is strongly linked with cytochrome c oxidase (complex
IV), where it helps transfer protons and maintain protein functionality [59, 141, 200–202].
The binding of PST to the headgroup of CL would limit its proton trapping ability, while
simultaneously stiffening the membrane. A stiffer membrane would limit the structural
flexibility of CL, likely limiting its interactions with cytochrome c oxidase as it would not
be able to fulfill its role of providing structural support to the enzyme [199, 200]. This
could greatly lower the efficiency of cytochrome c oxidase, possibly compromising the ETC.
A similar conclusion could be drawn regarding NADH:ubiquinone oxidoreductase (complex
I), where CL is responsible for regulating the membrane domains of the enzyme [16]. In a
similar fashion as described above, the association of PST with CL could change the way
CL interacts with the membrane domains of NADH:ubiquinone oxidoreductase, weakening
enzyme dynamics by weaking CL modulation. Taken together, the conceivable impact of
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PST on the complexes of the ETC could greatly lower the efficiency of said enzymes and
bring oxidative phosphorylation in cancer cells to a halt.
Intriguingly, PST could accelerate a well established apoptotic sequence that occurs in
the mitochondria. Also, literature shows a link between cytochrome c and apoptosis, where
the release of cytochrome c from the IMM begins an apoptotic cascade involving caspases
that degrade cell components and ultimately cause cell death [3, 60, 199, 203, 204]. CL
rich areas form a functional platform for cytochrome c, where CL changes the enzyme’s
usability and conformation [205–207]. A feasible mechanism of action for PST is shown in
Figure 5.2, where PST would obstruct cytochrome c from accessing the CL dense portions
of the membrane, forcing it to release from the IMM and consequently begin the caspase
cascade. Deficiencies in CL have shown an increase in apoptosis due to cytochrome c release
[204, 208], and PST could induce a similar effect by eliminating the functional capabilities of
CL. Furthermore, previous works show that PST enhances caspase protein activity [37, 99].
Our results suggest that the apoptotic power of PST may occur due to its ability to interact
with CL while simultaneously inhibiting cytochrome c interactions, leading to cancer cell
apoptosis.

Figure 5.2: Image depicting a hypothesized method of action for PST against cancerous
mitochondria. PST sits on the surface of the membrane where TOCL is highly concentrated
(green lipids), as opposed to the less ordered portion of the membrane (orange lipids).

Chapter 5. Discussion

47

The proposed method of action for PST is similar to the mechanism for doxorubicin, a
well studied anti-cancer agent. Doxorubicin induces apoptosis by releasing cytochrome c into
the intermembrane space [209–212]. This sets a precedent in that the proposed mechanism
for PST has been demonstrated in another anti-cancer molecule. One advantage PST has
over doxorubicin is that its not cytotoxic to healthy cells [213]. In conclusion, the results
suggest that PST may cause cell death in a similar manner to doxorubicin, but without the
negative toxic effects.

Chapter 6

Conclusion
In an effort to better understand the anti-cancer mechanism of PST on a molecular
level, various biophysical techniques were employed to determine how it interacts with
membranes. Data was collected using SANS, SAXS, NSE, and MD simulations, all of
which showed consistent results regarding PST’s condensing effect on TOCL containing
bilayers. Interestingly, PST was shown to have a stiffening effect on membrane dynamics
at biologically relevant concentrations, which correlated well with the bilayer structural
data. This increase in membrane rigidity could directly impact ETC complexes as it may
compromise their structural stability. The results from the RDF calculations and lipid chain
order show a clear affinity between PST and TOCL. In conclusion, the data presented in
this thesis established a connection between PST and TOCL bearing model membranes,
pointing to the possibility that the lipids of the IMM may be the target of PST. Furthermore,
a proposed mechanism of action was presented that will inspires future studies into the effect
of PST on CL membranes.
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Appendix A

Small-Angle Scattering Curves

Figure A.1: SANS (A) and SAXS (B) data from TOCL LUVs (open symbols) and the
corresponding fits (lines) to the SDP model.

Figure A.2: SANS (A) and SAXS (B) data from IMM mimic LUVs in the presence of 1
mol% PST (open symbols) and the corresponding fits (lines) to the SDP model.
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Figure A.3: SANS (A) and SAXS (B) data from IMM mimic LUVs in the presence of
1.5 mol% PST (open symbols) and the corresponding fits (lines) to the SDP model.

Figure A.4: SANS (A) and SAXS (B) data from IMM mimic LUVs in the presence of 2
mol% PST (open symbols) and the corresponding fits (lines) to the SDP model.

Figure A.5: SANS (A) and SAXS (B) data from IMM mimic LUVs in the presence of 1
vol% DMSO-d6 (open symbols) and the corresponding fits (lines) to the SDP model.
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Figure A.6: SANS (A) and SAXS (B) data from POPC/TOCL control LUVs (open
symbols) and the corresponding fits (lines) to the SDP model.

Figure A.7: SANS (A) and SAXS (B) data from POPC/TOCL control LUVs in the
presence of 1 mol% PST (open symbols) and the corresponding fits (lines) to the SDP
model.

Figure A.8: SAXS data from POPC/TOCL control LUVs in the presence of 2 mol%
PST (open symbols) and the corresponding fit (lines) to the SDP model.
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Figure A.9: SANS (A) and SAXS (B) data from POPE/TOCL control LUVs (open
symbols) and the corresponding fits (lines) to the SDP model.

Figure A.10: SANS (A) and SAXS (B) data from POPE/TOCL control LUVs in the
presence of 1 mol% PST (open symbols) and the corresponding fits (lines) to the SDP
model.

Figure A.11: SAXS data from POPE/TOCL control LUVs in the presence of 2 mol%
PST (open symbols) and the corresponding fit (lines) to the SDP model.
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Figure A.12: Zoomed in view of SANS data from D2 O (blue circles) and from D2 O with
1 vol% DMSO-d6 (red triangles).
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Appendix B

Intermediate Scattering Curves
and Decay Rates

Figure B.1: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B)
for the IMM mimic with 1 mol% PST. Error bars represent one standard deviation.
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Figure B.2: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B)
for the IMM mimic with 1.5 mol% PST. Error bars represent one standard deviation.

Figure B.3: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B)
for the IMM mimic with 2 mol% PST. Error bars represent one standard deviation.
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Figure B.4: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B)
for the IMM mimic with 1 vol% DMSO-d6. Error bars represent one standard deviation.

Figure B.5: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B)
for the POPC/TOCL control. Error bars represent one standard deviation.
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Figure B.6: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B) for
the POPC/TOCL control with 1 mol% PST. Error bars represent one standard deviation.

Figure B.7: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B)
for the POPE/TOCL control. Error bars represent one standard deviation.
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Figure B.8: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B) for
the POPE/TOCL control with 1 mol% PST. Error bars represent one standard deviation.

Figure B.9: The normalize intermediate scattering function I (Q,t)/I (Q,0) measured by
NSE (A) and the linear dependence of the relaxation rate (ΓZG ) with respect to Q3 (B) for
the POPE/TOCL control with 2 mol% PST. Error bars represent one standard deviation.
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Order Parameters

Figure C.1: Acyl chain order parameters extracted from MD simulations of the
POPC/TOCL control with 0, 1, and 2 mol% PST. Order parameters (SCH ) throughout
the length of the sn-1 (A and C) and sn-2 (B and D) acyl chains are shown for the lipids
that compose the POPC/TOCL control: TOCL (A and B) and POPC (C and D).
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Figure C.2: Acyl chain order parameters extracted from MD simulations of the
POPE/TOCL control with 0, 1, and 2 mol% PST. Order parameters (SCH ) throughout the
length of the sn-1 (A and C) and sn-2 (B and D) acyl chains are shown for the lipids that
compose the POPE/TOCL control: TOCL (A and B) and POPE (C and D).

Figure C.3: Acyl chain order parameters extracted from MD simulations of the TOCL
control. Order parameters (SCH ) throughout the length of the sn-1 (A) and sn-2 (B) acyl
chains are shown.
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PST Density Profiles

Figure D.1: PST density profiles extracted from MD runs of the POPC/TOCL bilayers
in the presence of 1 and 2 mol% PST. The numbers inserted at the maximum amplitude
of each curve correspond to the distance from bilayer center at which the maximum value
occurs.
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Figure D.2: PST density profiles extracted from MD runs of the POPE/TOCL bilayers
in the presence of 1 and 2 mol% PST. The numbers inserted at the maximum amplitude
of each curve correspond to the distance from bilayer center at which the maximum value
occurs.
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Radial Distribution Functions

Figure E.1: RDF graphs for MD simulations corresponding to the POPC/TOCL control
with 1 (A) and 2 (B) mol% PST.

Figure E.2: RDF graphs for MD simulations corresponding to the POPE/TOCL control
with 1 (A) and 2 (B) mol% PST.
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Wassall, John Katsaras, and Thad A. Harroun. Tocopherol Activity Correlates with
Its Location in a Membrane: A New Perspective on the Antioxidant Vitamin E.
Journal of the American Chemical Society, 135(20):7523–7533, May 2013. ISSN 00027863, 1520-5126. doi: 10.1021/ja312665r.
[26] Richard J. Alsop, Laura Toppozini, Drew Marquardt, Norbert Kučerka, Thad A.
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and Ilpo Vattulainen. Role of Cardiolipins in the Inner Mitochondrial Membrane: Insight Gained through Atom-Scale Simulations. The Journal of Physical Chemistry B,
113(11):3413–3422, March 2009. ISSN 1520-6106, 1520-5207. doi: 10.1021/jp8077369.
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